Long-term outcomes after MRI-guided focused ultrasound thalamotomy for medication-resistant essential tremor
Official title: A Prospective, Long-term Analysis of Clinical Outcomes in Patients Undergoing Magnetic Resonance-Guided Focused Ultrasound for Medication-Refractory Tremor
Run by Sunnybrook Health Sciences Centre · NCT07212244 · Data updated 2026-11-12
This project will see if MRI-guided focused ultrasound thalamotomy provides lasting tremor relief and good long-term safety for people whose essential tremor has not responded to medications.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 22 Years and up |
| Sex | All |
| Enrollment | 240 (estimated) |
| Sponsor | Sunnybrook Health Sciences Centre Academic / other |
| Locations | 1 site (Toronto, Ontario) |
| Status | Recruiting |
| Started | October 2025 |
| Main results expected | September 2031 |
| Study ends | September 2032 |
| Registry record updated | October 8, 2025 |
| Trial ID | NCT07212244 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults aged 22 or older with medication-refractory, moderate-to-severe hand-predominant essential tremor who are deemed suitable surgical candidates and can undergo MRI and attend follow-up visits.
✕Probably not a fit
People with MRI contraindications, significant medical comorbidities that make MRgFUS unsafe, those on anticoagulants near the procedure, or those whose tremor responds to medications are unlikely to benefit or be eligible.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This is a single-centre, prospective observational cohort of about 240 adults treated with MR-guided focused ultrasound (MRgFUS) thalamotomy as part of standard care at Sunnybrook Health Sciences Centre. Participants will be followed for a minimum of three years with scheduled clinical and neuropsychological assessments. Outcomes include tremor severity (CRST), quality of life (QUEST), ataxia rating (SARA), MRI imaging, and adverse event monitoring. The study aims to characterize durability of benefit and long-term neurological and quality-of-life effects after the procedure.
Why it matters
Potential benefit: If successful, the findings could show that MRgFUS thalamotomy delivers durable tremor reduction and improved quality of life with an acceptable long-term safety profile.
How similar studies have gone: Prior MRgFUS thalamotomy studies have shown meaningful short-to-mid-term tremor reduction, but prospective long-term (3+ year) outcome data remain limited.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Aged 22 years or older 2. Able and willing to give consent and to attend all visits 3. Diagnosed with essential tremor that is refractory to at least two first-line tremor medications 4. Confirmed to have moderate-to-severe hand tremor by the MRI guided Focused Ultrasound (MRgFUS) neurology team 5. Deemed suitable surgical candidates (decision-to-treat) by the MRgFUS neurosurgical team Exclusion Criteria: 1. Patients with standard contraindications to MRI such as non-MRI compatible implants or devices 2. Patients deemed clinically unfit to undergo MRgFUS thalamotomy due to health status including (but not limited to) pregnancy, advanced kidney disease, unstable cardiac status, severe hypertension, cerebrovascular disease, brain tumour, pulmonary disorders 3. Receiving anti-coagulants or drugs known to increase risk of hemorrhage within 2 weeks of MRgFUS procedure
Where it's running
-
Sunnybrook Health Sciences Centre
Toronto, Ontario, Canada Recruiting
Study contacts
- Study coordinator: Nir Lipsman, MD, PhD, FRCSC
- Email: Nir.Lipsman@sunnybrook.ca
- Phone: 416-480-6954
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Skin biopsy test for phosphorylated alpha‑synuclein to find which essential tremor patients are at risk for Parkinson's disease
This uses a small skin biopsy (Syn‑One) to see if phosphorylated alpha‑synuclein can identify people aged 50–85 with essential tremor who are more likely to develop Parkinson's disease.
-
Nighttime-adaptive deep brain stimulation for essential tremor
We will test whether using each patient’s thalamic sleep-related brain signals to automatically turn DBS off at night can reduce side effects while keeping tremor under control in people with essential tremor who already have Medtronic Percept implants.
-
Encora X1 in Daily Life for Essential Tremor
This real-world study tests how the Encora X1 wrist device affects day-to-day activities for adults with essential tremor over three years.
-
Intraoperative Microelectrode Recordings with MAVEN vs Standard Equipment
This study tests whether MAVEN can match the recording data collected during DBS surgery for movement disorders using standard equipment.
-
Microelectrode-based brain stimulation for Parkinson’s and essential tremor
This early feasibility test checks a new microelectrode-based brain stimulation method in adults with Parkinson’s disease or essential tremor who are already getting deep brain stimulation implants.
-
Non-Invasive Nerve Stimulation for Essential Tremor: Long-Term Safety and Effectiveness
This study tests whether a non-invasive stimulation device called TAPS helps reduce tremor in adults with essential tremor over a long period.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.